Plasminogen activator inhibitor (PAI-1) in plasma and platelets.
about
Increased 18F-FDG uptake is predictive of rupture in a novel rat abdominal aortic aneurysm rupture model.Purification of storage granule protein-23. A novel protein identified by phage display technology and interaction with type I plasminogen activator inhibitorPlatelets retain high levels of active plasminogen activator inhibitor 1Platelet granule secretion continuously prevents intratumor hemorrhage.Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: ultrastructural and pathogenic features.A new intracellular serine protease inhibitor expressed in the rat pituitary gland complexes with granzyme B.Endothelial cells organize fibrin clots into structures that are more resistant to lysis.Inhibition of microvascular endothelial cell proliferation by vitreous following retinal scatter photocoagulation.Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhagePeptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro.Plasminogen activators in inflammation and sepsis.Functional factor XIII-A is exposed on the stimulated platelet surfaceHistone deacetylase inhibition enhances tissue plasminogen activator release capacity in atherosclerotic man.Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow.How platelets safeguard vascular integrity.Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acidB-type natriuretic peptide is an independent predictor of endothelial function in man.Biomarkers of brain injury in the premature infant.Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients.Thrombin-anti-thrombin levels and patency of arterio-venous fistula in patients undergoing haemodialysis compared to healthy volunteers: a prospective analysis.Validating laboratory results in a national observational cohort study without field centers: the Reasons for Geographic and Racial Differences in Stroke cohort.Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study.Platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling and vascular integrity.Defective α2 antiplasmin cross-linking and thrombus stability in a case of acquired factor XIII deficiency.Global assays of fibrinolysis.Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activityDistribution of plasminogen activator inhibitor (PAI-1) in tissues.Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.Evaluating PAI-1 as a biomarker for stress in diving: human serum total PAI-1 is unaltered after 2 h dry exposures to 280 kPa hyperbaric air.A Case of Unexplained Cerebral Sinus Thrombosis in a 22-Year-Old Obese Caucasian WomanSodium nitroprusside modulates the fibrinolytic system in the rabbitModel thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysisTowards a multi-physics modelling framework for thrombolysis under the influence of blood flow.Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism.The role of Porphyromonas gingivalis gingipains in platelet activation and innate immune modulation.Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient.Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia.The plasma levels of prostanoids and plasminogen activator inhibitor-1 in primary and secondary thrombocytosis.Bioactivity-Guided Fractionation of the Traditional Chinese Medicine Resina Draconis Reveals Loureirin B as a PAI-1 Inhibitor.
P2860
Q27312594-B1C5FA0E-A960-40EE-98C5-B43AB7CC668AQ28584987-A335F6C4-6961-4999-B119-754AB258A6F1Q28743269-636F3950-73FE-4347-8DBA-67C685CED35EQ30483704-74C0A209-AEC1-409B-B282-EDB3B891BEC4Q31814794-409D1D5D-0EAC-415C-B2C6-CE92449FE0C4Q31942742-1F9AA182-345F-4E24-B72D-4ECD576E9B9EQ33220815-715D5262-CBF0-43DD-8D05-BACA33878403Q33256828-C4DB60D6-0FDE-42C2-8EF7-0BCD2CBAEC84Q33369958-EB0037EE-7C9E-42AA-B097-A3F0075E5758Q34220031-1DE3BA52-79C2-413C-A5E5-1CFFD9D59F98Q34777701-5B06815A-521A-4AD8-9CA7-417142F899F5Q35023065-2D3E7962-399F-4073-8BFE-9FA460808A88Q35217250-CC8AF97E-99C5-4A69-A670-182B604E97E6Q35450594-40B6DFE7-3181-4225-A8AC-ED4A28CF6E16Q35588157-560DF179-82F0-4586-B39D-FB2B3AC745FEQ35646892-9BBB61C5-1230-46C8-8200-61631C57F15CQ35964757-8954A3D5-DC83-48E1-9DE2-821AE415539CQ36550723-396EB4EC-8A36-4A1B-92DD-1EA48C5F9235Q36807586-317C02CF-8E2B-49B2-8682-8A4DF49B115FQ36976370-8B6BBB4A-A11A-4441-B579-ACDF778E09AAQ37287352-E74BD2D8-D6B5-4053-9095-48E93F3C9241Q37592722-EF460709-00FF-4079-813D-1BC0DBF6B279Q37725087-0939EA17-7AE7-4AA0-8ED2-C2AE1CFF8465Q38779362-D6A2DF45-BD79-40FA-BF7C-FB22FCCB455AQ39301841-696577D2-394C-4A6A-A90B-D792168D9569Q39330912-C25EE5AC-C068-499F-B723-CC83927B1682Q39463162-02DF5DA7-1837-4F9E-9ABF-76B7F57C08F3Q39630106-B75C3977-33AC-4AD4-AD5B-826E29750D74Q41760686-B8A40538-D6EE-41C6-A902-134FB976F7C0Q41821585-68ADCBE8-2CC1-4622-8736-09AD844B5E32Q41880321-79680658-18A6-4FEC-AB50-D4EB1DF48481Q41904806-2D4222D3-CEF2-4225-B2BC-AB45679484F3Q42102528-97E7BEED-7445-4225-A53F-2F682825BC67Q42157228-A60920BB-C397-46D8-9BB9-813182D0791AQ43591840-1CE5EF32-5917-4947-B7C5-FAA48291DF7DQ43683133-5BB0F573-8173-41A5-9B23-D83013E2BC9AQ45375279-3A594E39-C69A-444C-852A-C904155310F0Q46305789-A9ABBD5D-5776-4C1C-AA04-D59D4B2F450AQ46431034-C62037A6-ABA2-4E49-9207-68883EB95C83Q47168284-673E2E1B-541F-4356-9B31-052773F5FEA8
P2860
Plasminogen activator inhibitor (PAI-1) in plasma and platelets.
description
1988 nî lūn-bûn
@nan
1988 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
name
Plasminogen activator inhibitor (PAI-1) in plasma and platelets.
@ast
Plasminogen activator inhibitor (PAI-1) in plasma and platelets.
@en
type
label
Plasminogen activator inhibitor (PAI-1) in plasma and platelets.
@ast
Plasminogen activator inhibitor (PAI-1) in plasma and platelets.
@en
prefLabel
Plasminogen activator inhibitor (PAI-1) in plasma and platelets.
@ast
Plasminogen activator inhibitor (PAI-1) in plasma and platelets.
@en
P2093
P2860
P1476
Plasminogen activator inhibitor (PAI-1) in plasma and platelets.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2141.1988.TB02490.X
P407
P577
1988-11-01T00:00:00Z